Medical Education Library

This educational supplement was supported by Johnson & Johnson Consumer Products Company and is a supplement to Pediatric News.
This supplement was excerpted from a supplement to Seminars in Cutaneous Medicine and Surgery and Skin & Allergy News.

• Introduction
• Natural Ingredients and Atopic Dermatitis
   • Colloidal Oatmeal
   • Avenanthramides
   • Olive Oil
   • Shea Butter
• Summary

Faculty/Faculty Disclosures

Joseph Fowler, Jr., MD
Clinical Professor of Dermatology
University of Louisville
Louisville, Kentucky
Dr. Fowler has received funding for clinical research from, and is a consultant for, Johnson & Johnson Consumer Products.

Nanette Silverberg, MD
Director
Pediatric and Adolescent Dermatology
St. Luke's-Roosevelt Hospital Center
New York, New York
Dr. Silverberg has received funding for clinical research from Novartis and is a consultant for Johnson & Johnson Consumer Products.

Copyright © 2008 by Elsevier Inc.

To view the supplement, click the image above.

This educational supplement was supported by Johnson & Johnson Consumer Products Company and is a supplement to Pediatric News.
This supplement was excerpted from a supplement to Seminars in Cutaneous Medicine and Surgery and Skin & Allergy News.

• Introduction
• Natural Ingredients and Atopic Dermatitis
   • Colloidal Oatmeal
   • Avenanthramides
   • Olive Oil
   • Shea Butter
• Summary

Faculty/Faculty Disclosures

Joseph Fowler, Jr., MD
Clinical Professor of Dermatology
University of Louisville
Louisville, Kentucky
Dr. Fowler has received funding for clinical research from, and is a consultant for, Johnson & Johnson Consumer Products.

Nanette Silverberg, MD
Director
Pediatric and Adolescent Dermatology
St. Luke's-Roosevelt Hospital Center
New York, New York
Dr. Silverberg has received funding for clinical research from Novartis and is a consultant for Johnson & Johnson Consumer Products.

Copyright © 2008 by Elsevier Inc.

To view the supplement, click the image above.

This educational supplement was supported by Johnson & Johnson Consumer Products Company and is a supplement to Pediatric News.
This supplement was excerpted from a supplement to Seminars in Cutaneous Medicine and Surgery and Skin & Allergy News.

• Introduction
• Natural Ingredients and Atopic Dermatitis
   • Colloidal Oatmeal
   • Avenanthramides
   • Olive Oil
   • Shea Butter
• Summary

Faculty/Faculty Disclosures

Joseph Fowler, Jr., MD
Clinical Professor of Dermatology
University of Louisville
Louisville, Kentucky
Dr. Fowler has received funding for clinical research from, and is a consultant for, Johnson & Johnson Consumer Products.

Nanette Silverberg, MD
Director
Pediatric and Adolescent Dermatology
St. Luke's-Roosevelt Hospital Center
New York, New York
Dr. Silverberg has received funding for clinical research from Novartis and is a consultant for Johnson & Johnson Consumer Products.

Copyright © 2008 by Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
This supplement was sponsored by Johnson & Johnson Consumer Products Company.

• Introduction-Protecting the Infant Skin Barrier: Advances and Insights
• Comparison of Infant Skin Development in New Jersey, Mumbai, and Beijing (Stamatas et al)
• Cross-Cultural Differences in Infant and Toddler Sleep (Mindell et al)
• Development of Solar UVR-Related Pigmentation Begins as Early as the First Summer of Life (Mack et al)
• Efficacy of an Internet-Based Intervention for Infant and Toddler Sleep (Mindell et al)
• Impaired Skin Barrier Function in Mild and Moderate Diaper Dermatitis (Stamatas et al)
• Micronized Sunscreen Particles Were Not Shown to Penetrate Beyond the Stratum Corneum in Adults or Children (Stamatas et al)
• Survey of Bacterial Diversity on Infant Skin Over the First Year of Life (Capone et al)
• Technological Advances in Cleansers for Infants: A Historical Review and Look Towards the Future (Walters et al)
• Baby Sun Protection Products: A Competitive Assessment of Eye Mildness, SPF-PFA Ratio, Stability, and Antimicrobial Robustness (Bonner et al)
• A Case of Life-Threatening Infections Due to Preservative Absence in a Topical Cream and Audit Demonstrating Magnitude of the Problem (Sultan et al)
• Effect of Standardized Skin Care Regimens on Neonatal Skin Barrier Function in Different Body Areas (Bartels et al)

Faculty/Faculty Disclosures

PROFESSOR MICHAEL J. CORK, BSc, PhD, MB B Chir, FRCP
Head of Academic Unit of Dermatology Research
Department of Infection and Inflammation
Faculty of Medicine
The University of Sheffield, Beech Hill
Sheffield, England

PEGGY VERNON, RN, MA, CPNP
Pediatric Nurse Practitioner
Sorkin Dermatology
Greenwood Village, Colorado

Professor Cork is a consultant to Johnson and Johnson.

Ms Vernon has nothing to disclose.

Copyright © 2010 by Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
This supplement was sponsored by Johnson & Johnson Consumer Products Company.

• Introduction-Protecting the Infant Skin Barrier: Advances and Insights
• Comparison of Infant Skin Development in New Jersey, Mumbai, and Beijing (Stamatas et al)
• Cross-Cultural Differences in Infant and Toddler Sleep (Mindell et al)
• Development of Solar UVR-Related Pigmentation Begins as Early as the First Summer of Life (Mack et al)
• Efficacy of an Internet-Based Intervention for Infant and Toddler Sleep (Mindell et al)
• Impaired Skin Barrier Function in Mild and Moderate Diaper Dermatitis (Stamatas et al)
• Micronized Sunscreen Particles Were Not Shown to Penetrate Beyond the Stratum Corneum in Adults or Children (Stamatas et al)
• Survey of Bacterial Diversity on Infant Skin Over the First Year of Life (Capone et al)
• Technological Advances in Cleansers for Infants: A Historical Review and Look Towards the Future (Walters et al)
• Baby Sun Protection Products: A Competitive Assessment of Eye Mildness, SPF-PFA Ratio, Stability, and Antimicrobial Robustness (Bonner et al)
• A Case of Life-Threatening Infections Due to Preservative Absence in a Topical Cream and Audit Demonstrating Magnitude of the Problem (Sultan et al)
• Effect of Standardized Skin Care Regimens on Neonatal Skin Barrier Function in Different Body Areas (Bartels et al)

Faculty/Faculty Disclosures

PROFESSOR MICHAEL J. CORK, BSc, PhD, MB B Chir, FRCP
Head of Academic Unit of Dermatology Research
Department of Infection and Inflammation
Faculty of Medicine
The University of Sheffield, Beech Hill
Sheffield, England

PEGGY VERNON, RN, MA, CPNP
Pediatric Nurse Practitioner
Sorkin Dermatology
Greenwood Village, Colorado

Professor Cork is a consultant to Johnson and Johnson.

Ms Vernon has nothing to disclose.

Copyright © 2010 by Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
This supplement was sponsored by Johnson & Johnson Consumer Products Company.

• Introduction-Protecting the Infant Skin Barrier: Advances and Insights
• Comparison of Infant Skin Development in New Jersey, Mumbai, and Beijing (Stamatas et al)
• Cross-Cultural Differences in Infant and Toddler Sleep (Mindell et al)
• Development of Solar UVR-Related Pigmentation Begins as Early as the First Summer of Life (Mack et al)
• Efficacy of an Internet-Based Intervention for Infant and Toddler Sleep (Mindell et al)
• Impaired Skin Barrier Function in Mild and Moderate Diaper Dermatitis (Stamatas et al)
• Micronized Sunscreen Particles Were Not Shown to Penetrate Beyond the Stratum Corneum in Adults or Children (Stamatas et al)
• Survey of Bacterial Diversity on Infant Skin Over the First Year of Life (Capone et al)
• Technological Advances in Cleansers for Infants: A Historical Review and Look Towards the Future (Walters et al)
• Baby Sun Protection Products: A Competitive Assessment of Eye Mildness, SPF-PFA Ratio, Stability, and Antimicrobial Robustness (Bonner et al)
• A Case of Life-Threatening Infections Due to Preservative Absence in a Topical Cream and Audit Demonstrating Magnitude of the Problem (Sultan et al)
• Effect of Standardized Skin Care Regimens on Neonatal Skin Barrier Function in Different Body Areas (Bartels et al)

Faculty/Faculty Disclosures

PROFESSOR MICHAEL J. CORK, BSc, PhD, MB B Chir, FRCP
Head of Academic Unit of Dermatology Research
Department of Infection and Inflammation
Faculty of Medicine
The University of Sheffield, Beech Hill
Sheffield, England

PEGGY VERNON, RN, MA, CPNP
Pediatric Nurse Practitioner
Sorkin Dermatology
Greenwood Village, Colorado

Professor Cork is a consultant to Johnson and Johnson.

Ms Vernon has nothing to disclose.

Copyright © 2010 by Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News and supported by SkinMedical.
This supplement is based on a faculty clinical roundtable discussion held September 29, 2007, in San Francisco, California.
 

• Epidemiology and Pathogenesis

• Treatment Goals and Approaches

• Core Therapy

• Microbial Colonization and Infection

• Adherence Issues

• Topical Steroids: Choices and Issues

• HPA-Axis Suppression

• A New Steroid Option

• Incorporating New Therapy Into Practice

• Summary Comments and Observations

Faculty/Faculty Disclosure

Lawrence F. Eichenfield, MD
Moderator
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego
Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital
San Diego, California
Dr. Eichenfield has disclosed that he is an investigator for and has received research grants and support from Hill Dermaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Stiefel Laboratories, Inc. He also is a consultant to and on the advisory board of Astellas Pharma Inc., Graceway Pharmaceuticals, LLC, Novartis, Stiefel, and SkinMedica, Inc.

Robert G. Greenberg, MD
Private Practice
Director, East Bay Psoriasis Treatment Center
San Ramon, California
Dr. Greenberg has disclosed that he is a consultant to and on the speaker's bureau for Abbott Laboratories, Amgen Inc., CollaGenex Pharmaceuticals Inc., Dermik Laboratories, Galderma Laboratories, L.P., Genentech, Inc., Medicis Pharmaceutical Corporation, SkinMedica, Stiefel, and Warner Chilcott.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Kentucky
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Laboratories, Abbott, Acambis, Allergan Inc., Amgen, Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex, CombiMatrix, Coria Laboratories, Ltd., Dermik, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma, Genentech, GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis, Merck Serono, NanoBio Corporation, Novartis, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Stiefel, ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Amy S. Paller, MD
Walter J. Hamlin Professor and Chair
Department of Dermatology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Dr. Paller has disclosed that she is a consultant to Astellas, Novartis, SkinMedica, and Stiefel.

Rebecca L. Smith, MD
Fort Mill Dermatology, LLC
Fort Mill, South Carolina
Dr. Smith has disclosed that she is a consultant to Coria, SkinMedica, and Stiefel.

Copyright © 2007 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News and supported by SkinMedical.
This supplement is based on a faculty clinical roundtable discussion held September 29, 2007, in San Francisco, California.
 

• Epidemiology and Pathogenesis

• Treatment Goals and Approaches

• Core Therapy

• Microbial Colonization and Infection

• Adherence Issues

• Topical Steroids: Choices and Issues

• HPA-Axis Suppression

• A New Steroid Option

• Incorporating New Therapy Into Practice

• Summary Comments and Observations

Faculty/Faculty Disclosure

Lawrence F. Eichenfield, MD
Moderator
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego
Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital
San Diego, California
Dr. Eichenfield has disclosed that he is an investigator for and has received research grants and support from Hill Dermaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Stiefel Laboratories, Inc. He also is a consultant to and on the advisory board of Astellas Pharma Inc., Graceway Pharmaceuticals, LLC, Novartis, Stiefel, and SkinMedica, Inc.

Robert G. Greenberg, MD
Private Practice
Director, East Bay Psoriasis Treatment Center
San Ramon, California
Dr. Greenberg has disclosed that he is a consultant to and on the speaker's bureau for Abbott Laboratories, Amgen Inc., CollaGenex Pharmaceuticals Inc., Dermik Laboratories, Galderma Laboratories, L.P., Genentech, Inc., Medicis Pharmaceutical Corporation, SkinMedica, Stiefel, and Warner Chilcott.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Kentucky
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Laboratories, Abbott, Acambis, Allergan Inc., Amgen, Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex, CombiMatrix, Coria Laboratories, Ltd., Dermik, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma, Genentech, GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis, Merck Serono, NanoBio Corporation, Novartis, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Stiefel, ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Amy S. Paller, MD
Walter J. Hamlin Professor and Chair
Department of Dermatology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Dr. Paller has disclosed that she is a consultant to Astellas, Novartis, SkinMedica, and Stiefel.

Rebecca L. Smith, MD
Fort Mill Dermatology, LLC
Fort Mill, South Carolina
Dr. Smith has disclosed that she is a consultant to Coria, SkinMedica, and Stiefel.

Copyright © 2007 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News and supported by SkinMedical.
This supplement is based on a faculty clinical roundtable discussion held September 29, 2007, in San Francisco, California.
 

• Epidemiology and Pathogenesis

• Treatment Goals and Approaches

• Core Therapy

• Microbial Colonization and Infection

• Adherence Issues

• Topical Steroids: Choices and Issues

• HPA-Axis Suppression

• A New Steroid Option

• Incorporating New Therapy Into Practice

• Summary Comments and Observations

Faculty/Faculty Disclosure

Lawrence F. Eichenfield, MD
Moderator
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego
Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital
San Diego, California
Dr. Eichenfield has disclosed that he is an investigator for and has received research grants and support from Hill Dermaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Stiefel Laboratories, Inc. He also is a consultant to and on the advisory board of Astellas Pharma Inc., Graceway Pharmaceuticals, LLC, Novartis, Stiefel, and SkinMedica, Inc.

Robert G. Greenberg, MD
Private Practice
Director, East Bay Psoriasis Treatment Center
San Ramon, California
Dr. Greenberg has disclosed that he is a consultant to and on the speaker's bureau for Abbott Laboratories, Amgen Inc., CollaGenex Pharmaceuticals Inc., Dermik Laboratories, Galderma Laboratories, L.P., Genentech, Inc., Medicis Pharmaceutical Corporation, SkinMedica, Stiefel, and Warner Chilcott.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Kentucky
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Laboratories, Abbott, Acambis, Allergan Inc., Amgen, Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex, CombiMatrix, Coria Laboratories, Ltd., Dermik, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma, Genentech, GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis, Merck Serono, NanoBio Corporation, Novartis, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Stiefel, ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Amy S. Paller, MD
Walter J. Hamlin Professor and Chair
Department of Dermatology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Dr. Paller has disclosed that she is a consultant to Astellas, Novartis, SkinMedica, and Stiefel.

Rebecca L. Smith, MD
Fort Mill Dermatology, LLC
Fort Mill, South Carolina
Dr. Smith has disclosed that she is a consultant to Coria, SkinMedica, and Stiefel.

Copyright © 2007 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
Funding for this supplement was provided by Wyeth Pharmaceuticals, Collegeville, PA.
This supplement was developed from scientific information presented at the 2009 European Society for Pediatric Infectious Diseases (ESPID) convened in Brussels, Belgium, June 9-13, 2009.

Topic Highlights

• Introduction
• Risk Factors for Bacterial Nasopharyngeal Carriage and the Effect of PCV7
• Changes in Carriage of Streptococcus pneumoniae in Children Attending Day Care Centres (DCCs) in Coimbra, Portugal
• Dynamic Epidemiology of Nasopharyngeal Flora in Kindergarten Children
• Prevalence of Streptococcus pneumoniae Nasal Carriage Among Children With Community Acquired Respiratory Tract Infections
• Effect of a Reduced Dose Infant Schedule of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) on Nasopharyngeal Pneumococcal Carriage (NP-PNC-CARR)
• Nasopharyngeal Microbiota During Upper Respiratory Infection: Comparison Between Children With and Without Acute Otitis Media

Faculty/Faculty Disclosures

Ron Dagan, MD
Professor of Pediatrics and Infectious Disease
Pediatric Infectious Disease Unit
Soroka University Medical Center
Facility of Health Sciences
Ben-Gurion University of the Negev, Beer-Sheva, Israel
Dr. Dagan discloses that in the past 48 months, he has been a scientific consultant for Berna/Crucell, GlaxoSmithKline, Merck, Novartis, Protea, and Wyeth; has been a speaker for Berna/Crucell, GlaxoSmithKline, and Wyeth; has received grant or research support from Berna/Crucell, Merck, and Wyeth; and is a shareholder in Protea.
 

Copyright © 2009 by Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
Funding for this supplement was provided by Wyeth Pharmaceuticals, Collegeville, PA.
This supplement was developed from scientific information presented at the 2009 European Society for Pediatric Infectious Diseases (ESPID) convened in Brussels, Belgium, June 9-13, 2009.

Topic Highlights

• Introduction
• Risk Factors for Bacterial Nasopharyngeal Carriage and the Effect of PCV7
• Changes in Carriage of Streptococcus pneumoniae in Children Attending Day Care Centres (DCCs) in Coimbra, Portugal
• Dynamic Epidemiology of Nasopharyngeal Flora in Kindergarten Children
• Prevalence of Streptococcus pneumoniae Nasal Carriage Among Children With Community Acquired Respiratory Tract Infections
• Effect of a Reduced Dose Infant Schedule of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) on Nasopharyngeal Pneumococcal Carriage (NP-PNC-CARR)
• Nasopharyngeal Microbiota During Upper Respiratory Infection: Comparison Between Children With and Without Acute Otitis Media

Faculty/Faculty Disclosures

Ron Dagan, MD
Professor of Pediatrics and Infectious Disease
Pediatric Infectious Disease Unit
Soroka University Medical Center
Facility of Health Sciences
Ben-Gurion University of the Negev, Beer-Sheva, Israel
Dr. Dagan discloses that in the past 48 months, he has been a scientific consultant for Berna/Crucell, GlaxoSmithKline, Merck, Novartis, Protea, and Wyeth; has been a speaker for Berna/Crucell, GlaxoSmithKline, and Wyeth; has received grant or research support from Berna/Crucell, Merck, and Wyeth; and is a shareholder in Protea.
 

Copyright © 2009 by Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
Funding for this supplement was provided by Wyeth Pharmaceuticals, Collegeville, PA.
This supplement was developed from scientific information presented at the 2009 European Society for Pediatric Infectious Diseases (ESPID) convened in Brussels, Belgium, June 9-13, 2009.

Topic Highlights

• Introduction
• Risk Factors for Bacterial Nasopharyngeal Carriage and the Effect of PCV7
• Changes in Carriage of Streptococcus pneumoniae in Children Attending Day Care Centres (DCCs) in Coimbra, Portugal
• Dynamic Epidemiology of Nasopharyngeal Flora in Kindergarten Children
• Prevalence of Streptococcus pneumoniae Nasal Carriage Among Children With Community Acquired Respiratory Tract Infections
• Effect of a Reduced Dose Infant Schedule of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) on Nasopharyngeal Pneumococcal Carriage (NP-PNC-CARR)
• Nasopharyngeal Microbiota During Upper Respiratory Infection: Comparison Between Children With and Without Acute Otitis Media

Faculty/Faculty Disclosures

Ron Dagan, MD
Professor of Pediatrics and Infectious Disease
Pediatric Infectious Disease Unit
Soroka University Medical Center
Facility of Health Sciences
Ben-Gurion University of the Negev, Beer-Sheva, Israel
Dr. Dagan discloses that in the past 48 months, he has been a scientific consultant for Berna/Crucell, GlaxoSmithKline, Merck, Novartis, Protea, and Wyeth; has been a speaker for Berna/Crucell, GlaxoSmithKline, and Wyeth; has received grant or research support from Berna/Crucell, Merck, and Wyeth; and is a shareholder in Protea.
 

Copyright © 2009 by Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
The supplement is based on proceedings from the Skin Hydration Summit held on Saturday, March 17, 2007, in New York, New York. This supplement was supported by Unilever.

• Foreward

• Introduction

• Stratum Corneum: Physiology and the Role of Hydration

• Cleanser Choice Matters

• Moisturizers
  • Moisturizers With Sun Protection

• Talking to Patients About Skin Care

• Importance of a Skin Care Regimen
  • Acne
  • Atopic Dermatitis
  • Sensitive Skin
  • Additional Skin Conditions

• Patient Compliance: Practical Tips

• Summary

Faculty/Faculty Disclosure

Leslie S. Baumann, MD
Chief, Division of Cosmetic Dermatology
Professor, Clinical Dermatology
University of Miami School of Medicine
Miami, Florida
Dr. Baumann has received funding for clinical grants from Allergan, Inc., Avon Products, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, Stiefel Laboratories, and Unilever PLC.

Diane S. Berson, MD, FAAD
Assistant Professor, Department of Dermatology
Weill Medical College of Cornell University
Assistant Attending Dermatologist
New York-Presbyterian Hospital
New York, New York
Dr. Berson is a consultant to Kao Brands and OrthoNeutrogena. She has received funding for clinical grants from CollaGenex, Inc., DUSA Pharmaceuticals, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, and Stiefel Laboratories.

Fran E. Cook-Bolden, MD
Clinical Assistant Professor, Dermatology
College of Physicians and Surgeons
Columbia University
Attending Physician, Dermatology
St. Luke's-Roosevelt Hospital Center
New York, New York
Dr. Cook-Bolden has nothing to disclose.

David J. Goldberg, MD, JD
Clinical Professor, Dermatology
Director, Laser Research
Mount Sinai School of Medicine
New York, New York
Clinical Professor, Dermatology
Chief, Dermatologic Surgery
University of Medicine and Dentistry of New Jersey-New Jersey Medical School
Newark, New Jersey
Dr. Goldberg has nothing to disclose.

Jennifer H. Goldwasser, MD
Clinical Assistant Professor, Dermatology
New York Medical College
Valhalla, New York
Assistant Attending Physician, Dermatology
White Plains Hospital Center
White Plains, New York
Dr. Goldwasser has nothing to disclose.

Copyright © 2007 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
The supplement is based on proceedings from the Skin Hydration Summit held on Saturday, March 17, 2007, in New York, New York. This supplement was supported by Unilever.

• Foreward

• Introduction

• Stratum Corneum: Physiology and the Role of Hydration

• Cleanser Choice Matters

• Moisturizers
  • Moisturizers With Sun Protection

• Talking to Patients About Skin Care

• Importance of a Skin Care Regimen
  • Acne
  • Atopic Dermatitis
  • Sensitive Skin
  • Additional Skin Conditions

• Patient Compliance: Practical Tips

• Summary

Faculty/Faculty Disclosure

Leslie S. Baumann, MD
Chief, Division of Cosmetic Dermatology
Professor, Clinical Dermatology
University of Miami School of Medicine
Miami, Florida
Dr. Baumann has received funding for clinical grants from Allergan, Inc., Avon Products, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, Stiefel Laboratories, and Unilever PLC.

Diane S. Berson, MD, FAAD
Assistant Professor, Department of Dermatology
Weill Medical College of Cornell University
Assistant Attending Dermatologist
New York-Presbyterian Hospital
New York, New York
Dr. Berson is a consultant to Kao Brands and OrthoNeutrogena. She has received funding for clinical grants from CollaGenex, Inc., DUSA Pharmaceuticals, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, and Stiefel Laboratories.

Fran E. Cook-Bolden, MD
Clinical Assistant Professor, Dermatology
College of Physicians and Surgeons
Columbia University
Attending Physician, Dermatology
St. Luke's-Roosevelt Hospital Center
New York, New York
Dr. Cook-Bolden has nothing to disclose.

David J. Goldberg, MD, JD
Clinical Professor, Dermatology
Director, Laser Research
Mount Sinai School of Medicine
New York, New York
Clinical Professor, Dermatology
Chief, Dermatologic Surgery
University of Medicine and Dentistry of New Jersey-New Jersey Medical School
Newark, New Jersey
Dr. Goldberg has nothing to disclose.

Jennifer H. Goldwasser, MD
Clinical Assistant Professor, Dermatology
New York Medical College
Valhalla, New York
Assistant Attending Physician, Dermatology
White Plains Hospital Center
White Plains, New York
Dr. Goldwasser has nothing to disclose.

Copyright © 2007 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
The supplement is based on proceedings from the Skin Hydration Summit held on Saturday, March 17, 2007, in New York, New York. This supplement was supported by Unilever.

• Foreward

• Introduction

• Stratum Corneum: Physiology and the Role of Hydration

• Cleanser Choice Matters

• Moisturizers
  • Moisturizers With Sun Protection

• Talking to Patients About Skin Care

• Importance of a Skin Care Regimen
  • Acne
  • Atopic Dermatitis
  • Sensitive Skin
  • Additional Skin Conditions

• Patient Compliance: Practical Tips

• Summary

Faculty/Faculty Disclosure

Leslie S. Baumann, MD
Chief, Division of Cosmetic Dermatology
Professor, Clinical Dermatology
University of Miami School of Medicine
Miami, Florida
Dr. Baumann has received funding for clinical grants from Allergan, Inc., Avon Products, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, Stiefel Laboratories, and Unilever PLC.

Diane S. Berson, MD, FAAD
Assistant Professor, Department of Dermatology
Weill Medical College of Cornell University
Assistant Attending Dermatologist
New York-Presbyterian Hospital
New York, New York
Dr. Berson is a consultant to Kao Brands and OrthoNeutrogena. She has received funding for clinical grants from CollaGenex, Inc., DUSA Pharmaceuticals, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, and Stiefel Laboratories.

Fran E. Cook-Bolden, MD
Clinical Assistant Professor, Dermatology
College of Physicians and Surgeons
Columbia University
Attending Physician, Dermatology
St. Luke's-Roosevelt Hospital Center
New York, New York
Dr. Cook-Bolden has nothing to disclose.

David J. Goldberg, MD, JD
Clinical Professor, Dermatology
Director, Laser Research
Mount Sinai School of Medicine
New York, New York
Clinical Professor, Dermatology
Chief, Dermatologic Surgery
University of Medicine and Dentistry of New Jersey-New Jersey Medical School
Newark, New Jersey
Dr. Goldberg has nothing to disclose.

Jennifer H. Goldwasser, MD
Clinical Assistant Professor, Dermatology
New York Medical College
Valhalla, New York
Assistant Attending Physician, Dermatology
White Plains Hospital Center
White Plains, New York
Dr. Goldwasser has nothing to disclose.

Copyright © 2007 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News, supported by Endo Pharmaceuticals. This supplement is based on a physician interview.

William T. Zempsky, MD
Associate Director
Pain Relief Program
Connecticut Children's Medical Center
Hartford
Dr. Zempsky has received clinical grants from Anesiva, Inc., Sontra Medical Corporation, and Vyteris, Inc. He is a consultant to Anesiva and Endo Pharmaceuticals.

Topic Highlights

Lidocaine/Tetracaine Anesthesia Patch: Summaries of Three Clinical Studies

• A Lidocaine/Tetracaine Patch for Local Anesthesia Prior to Vascular Access Procedures in Children: Results From Two Randomized Controlled Studies

• Contribution of a Heating Element to Topical Anesthesia Patch Efficacy: A Randomized, Double-Blind Study

• The Lidocaine/Tetracaine Patch Versus EMLA for Topical Local Anesthesia Before a Vascular Access Procedure: A Randomized Controlled Trial

Copyright © 2007 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News, supported by Endo Pharmaceuticals. This supplement is based on a physician interview.

William T. Zempsky, MD
Associate Director
Pain Relief Program
Connecticut Children's Medical Center
Hartford
Dr. Zempsky has received clinical grants from Anesiva, Inc., Sontra Medical Corporation, and Vyteris, Inc. He is a consultant to Anesiva and Endo Pharmaceuticals.

Topic Highlights

Lidocaine/Tetracaine Anesthesia Patch: Summaries of Three Clinical Studies

• A Lidocaine/Tetracaine Patch for Local Anesthesia Prior to Vascular Access Procedures in Children: Results From Two Randomized Controlled Studies

• Contribution of a Heating Element to Topical Anesthesia Patch Efficacy: A Randomized, Double-Blind Study

• The Lidocaine/Tetracaine Patch Versus EMLA for Topical Local Anesthesia Before a Vascular Access Procedure: A Randomized Controlled Trial

Copyright © 2007 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News, supported by Endo Pharmaceuticals. This supplement is based on a physician interview.

William T. Zempsky, MD
Associate Director
Pain Relief Program
Connecticut Children's Medical Center
Hartford
Dr. Zempsky has received clinical grants from Anesiva, Inc., Sontra Medical Corporation, and Vyteris, Inc. He is a consultant to Anesiva and Endo Pharmaceuticals.

Topic Highlights

Lidocaine/Tetracaine Anesthesia Patch: Summaries of Three Clinical Studies

• A Lidocaine/Tetracaine Patch for Local Anesthesia Prior to Vascular Access Procedures in Children: Results From Two Randomized Controlled Studies

• Contribution of a Heating Element to Topical Anesthesia Patch Efficacy: A Randomized, Double-Blind Study

• The Lidocaine/Tetracaine Patch Versus EMLA for Topical Local Anesthesia Before a Vascular Access Procedure: A Randomized Controlled Trial

Copyright © 2007 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
This supplement was supported by PharmaDerm®
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 31st Annual Hawaii Dermatology Seminar, a continuing medical education program, on March 6, 2007, in Maui, Hawaii.

Topical Steroids in Pediatric Atopic Dermatitis
Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Indianapolis, Ind.
Medical Director
Derm Research, PLLC
Louisville, Ky.
Dr. Kircik has received funding for clinical grants from and is a consultant to Abbott Laboratories, Acambis, Allergan, Inc., Amgen Inc., Astellas Pharma US (Fujisawa), Berlex, Inc., Biogen-Idec, Inc., Breckenridge Pharmaceutical, Centocor, Inc., CollaGenex, Inc., CombiMatrix Corporation, Connetics Corporation, Coria Laboratories, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Galderma Laboratories, L.P., Genentech Inc., GlaxoSmith Kline, Healthpoint Ltd., Intendis GmbH, 3M Pharmaceuticals, Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceuticals, OrthoNeutrogena Corporation, PharmaDerm, QLT Inc., QuatRx Pharmaceuticals, Serono S.A., SkinMedica, Inc., and Stiefel Laboratories, Inc. Dr. Kircik has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.

Topical Antifungals: An Update
Douglas W. Kress, MD
Chief of Pediatric Dermatology
Children's Hospital of Pittsburgh
Pittsburgh, Penn.
Dr. Kress has received honoraria, grant funding, and has served on the advisory board for PharmaDerm. Dr. Kress has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.

Target Audience

This activity is intended for health care professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with atopic dermatitis.

Copyright © 2007 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
This supplement was supported by PharmaDerm®
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 31st Annual Hawaii Dermatology Seminar, a continuing medical education program, on March 6, 2007, in Maui, Hawaii.

Topical Steroids in Pediatric Atopic Dermatitis
Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Indianapolis, Ind.
Medical Director
Derm Research, PLLC
Louisville, Ky.
Dr. Kircik has received funding for clinical grants from and is a consultant to Abbott Laboratories, Acambis, Allergan, Inc., Amgen Inc., Astellas Pharma US (Fujisawa), Berlex, Inc., Biogen-Idec, Inc., Breckenridge Pharmaceutical, Centocor, Inc., CollaGenex, Inc., CombiMatrix Corporation, Connetics Corporation, Coria Laboratories, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Galderma Laboratories, L.P., Genentech Inc., GlaxoSmith Kline, Healthpoint Ltd., Intendis GmbH, 3M Pharmaceuticals, Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceuticals, OrthoNeutrogena Corporation, PharmaDerm, QLT Inc., QuatRx Pharmaceuticals, Serono S.A., SkinMedica, Inc., and Stiefel Laboratories, Inc. Dr. Kircik has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.

Topical Antifungals: An Update
Douglas W. Kress, MD
Chief of Pediatric Dermatology
Children's Hospital of Pittsburgh
Pittsburgh, Penn.
Dr. Kress has received honoraria, grant funding, and has served on the advisory board for PharmaDerm. Dr. Kress has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.

Target Audience

This activity is intended for health care professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with atopic dermatitis.

Copyright © 2007 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
This supplement was supported by PharmaDerm®
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 31st Annual Hawaii Dermatology Seminar, a continuing medical education program, on March 6, 2007, in Maui, Hawaii.

Topical Steroids in Pediatric Atopic Dermatitis
Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Indianapolis, Ind.
Medical Director
Derm Research, PLLC
Louisville, Ky.
Dr. Kircik has received funding for clinical grants from and is a consultant to Abbott Laboratories, Acambis, Allergan, Inc., Amgen Inc., Astellas Pharma US (Fujisawa), Berlex, Inc., Biogen-Idec, Inc., Breckenridge Pharmaceutical, Centocor, Inc., CollaGenex, Inc., CombiMatrix Corporation, Connetics Corporation, Coria Laboratories, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Galderma Laboratories, L.P., Genentech Inc., GlaxoSmith Kline, Healthpoint Ltd., Intendis GmbH, 3M Pharmaceuticals, Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceuticals, OrthoNeutrogena Corporation, PharmaDerm, QLT Inc., QuatRx Pharmaceuticals, Serono S.A., SkinMedica, Inc., and Stiefel Laboratories, Inc. Dr. Kircik has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.

Topical Antifungals: An Update
Douglas W. Kress, MD
Chief of Pediatric Dermatology
Children's Hospital of Pittsburgh
Pittsburgh, Penn.
Dr. Kress has received honoraria, grant funding, and has served on the advisory board for PharmaDerm. Dr. Kress has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.

Target Audience

This activity is intended for health care professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with atopic dermatitis.

Copyright © 2007 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
Supported by Stiefel.
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, held February 13, 2006, in Kauai, Hawaii.

• Introduction
• The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris
• Combination Therapy Considerations in Acne Vulgaris
• Evolving Therapy in Atopic Dermatitis
• Nonsteroidal Treatment of Atopic Dermatitis

Faculty/Faculty Disclosure Statement

Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
University of California, Davis School of Medicine
Medical Director
Center for Dermatology and Laser Surgery
Sacramento
Dr. Tanghetti has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.

Leon Kircik, MD
Clinical Associate Professor
Division of Dermatology
Indiana University
Indianapolis
Medical Director
Physicians Skin Care, PLLC
Louisville, Ky.
Dr. Kircik has received funding as an investigator, consultant, advisor, or speaker from Abbott Laboratories, Allergan Inc., Amgen, Inc., Astellas Pharma US, Inc., Berlex Inc., Biogen Idec Inc., Centocor, Inc., Connetics Corporation, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech Inc., GlaxoSmithKline, HealthPoint Ltd., Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceutical Corporation, QLT Inc., SkinMedica, Stiefel Laboratories, Inc., 3M Pharmaceuticals, Valeant Pharmaceuticals International, and Warner-Chilcott, PLC. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: clindamycin 1% benzoyl peroxide 5% gel (Duac Topical Gel) for acne.

Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Children's Hospital
San Diego
Dr. Eichenfield has received clinical grants from Astellas Pharma US, Inc., Connetics Corporation, Dermik Laboratories, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, Hill Dermacueticals, Inc., and Novartis Pharmaceuticals Corporation. He is also a consultant to Connetics and Novartis. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis, MAS063D (Atopiclair) for atopic dermatitis, and a probiotic, Lactobacillus fermentum, for atopic dermatitis.

James Turner, MD, PhD
Clinical Professor
Division of Dermatology
Department of Medicine
University of Tennessee
Memphis
Dr. Turner is a consultant to Stiefel Laboratories, Inc. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis and clindamycin 1% benzoyl peroxide 5% gel.

Target Audience

This activity is intended for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris or atopic dermatitis.

Copyright © 2006 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
Supported by Stiefel.
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, held February 13, 2006, in Kauai, Hawaii.

• Introduction
• The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris
• Combination Therapy Considerations in Acne Vulgaris
• Evolving Therapy in Atopic Dermatitis
• Nonsteroidal Treatment of Atopic Dermatitis

Faculty/Faculty Disclosure Statement

Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
University of California, Davis School of Medicine
Medical Director
Center for Dermatology and Laser Surgery
Sacramento
Dr. Tanghetti has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.

Leon Kircik, MD
Clinical Associate Professor
Division of Dermatology
Indiana University
Indianapolis
Medical Director
Physicians Skin Care, PLLC
Louisville, Ky.
Dr. Kircik has received funding as an investigator, consultant, advisor, or speaker from Abbott Laboratories, Allergan Inc., Amgen, Inc., Astellas Pharma US, Inc., Berlex Inc., Biogen Idec Inc., Centocor, Inc., Connetics Corporation, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech Inc., GlaxoSmithKline, HealthPoint Ltd., Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceutical Corporation, QLT Inc., SkinMedica, Stiefel Laboratories, Inc., 3M Pharmaceuticals, Valeant Pharmaceuticals International, and Warner-Chilcott, PLC. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: clindamycin 1% benzoyl peroxide 5% gel (Duac Topical Gel) for acne.

Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Children's Hospital
San Diego
Dr. Eichenfield has received clinical grants from Astellas Pharma US, Inc., Connetics Corporation, Dermik Laboratories, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, Hill Dermacueticals, Inc., and Novartis Pharmaceuticals Corporation. He is also a consultant to Connetics and Novartis. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis, MAS063D (Atopiclair) for atopic dermatitis, and a probiotic, Lactobacillus fermentum, for atopic dermatitis.

James Turner, MD, PhD
Clinical Professor
Division of Dermatology
Department of Medicine
University of Tennessee
Memphis
Dr. Turner is a consultant to Stiefel Laboratories, Inc. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis and clindamycin 1% benzoyl peroxide 5% gel.

Target Audience

This activity is intended for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris or atopic dermatitis.

Copyright © 2006 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
Supported by Stiefel.
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 30th Annual Hawaii Dermatology Seminar, held February 13, 2006, in Kauai, Hawaii.

• Introduction
• The Importance of Vehicle and Skin Barrier Function in Acne Vulgaris
• Combination Therapy Considerations in Acne Vulgaris
• Evolving Therapy in Atopic Dermatitis
• Nonsteroidal Treatment of Atopic Dermatitis

Faculty/Faculty Disclosure Statement

Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
University of California, Davis School of Medicine
Medical Director
Center for Dermatology and Laser Surgery
Sacramento
Dr. Tanghetti has received funding for clinical grants from and is a consultant to Allergan Inc., and Stiefel Laboratories, Inc.

Leon Kircik, MD
Clinical Associate Professor
Division of Dermatology
Indiana University
Indianapolis
Medical Director
Physicians Skin Care, PLLC
Louisville, Ky.
Dr. Kircik has received funding as an investigator, consultant, advisor, or speaker from Abbott Laboratories, Allergan Inc., Amgen, Inc., Astellas Pharma US, Inc., Berlex Inc., Biogen Idec Inc., Centocor, Inc., Connetics Corporation, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech Inc., GlaxoSmithKline, HealthPoint Ltd., Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceutical Corporation, QLT Inc., SkinMedica, Stiefel Laboratories, Inc., 3M Pharmaceuticals, Valeant Pharmaceuticals International, and Warner-Chilcott, PLC. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: clindamycin 1% benzoyl peroxide 5% gel (Duac Topical Gel) for acne.

Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego, School of Medicine
Children's Hospital
San Diego
Dr. Eichenfield has received clinical grants from Astellas Pharma US, Inc., Connetics Corporation, Dermik Laboratories, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., GlaxoSmithKline, Hill Dermacueticals, Inc., and Novartis Pharmaceuticals Corporation. He is also a consultant to Connetics and Novartis. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis, MAS063D (Atopiclair) for atopic dermatitis, and a probiotic, Lactobacillus fermentum, for atopic dermatitis.

James Turner, MD, PhD
Clinical Professor
Division of Dermatology
Department of Medicine
University of Tennessee
Memphis
Dr. Turner is a consultant to Stiefel Laboratories, Inc. He has stated that he will reference the unlabeled/unapproved uses of the following drugs: MimyX cream for atopic dermatitis and clindamycin 1% benzoyl peroxide 5% gel.

Target Audience

This activity is intended for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris or atopic dermatitis.

Copyright © 2006 Elsevier Inc.

To view the supplement, click the image above.

A supplement to Pediatric News.
Supported by an educational grant from Stiefel.
The articles in this supplement are based on presentations made during the Skin Disease Education Foundation's 29th Annual Hawaii Dermatology Seminar, on March 18-24, 2005, in Maui, Hawaii.

• The Importance of Vehicle in Acne Therapy
• Acne Management: Treatment Strategies and Challenges
• Cosmetic Management of Patients with Acne Vulgaris and Acne Rosacea
• The Resurgence of Benzoyl Peroxide in Acne Therapy
• New Treatment Options for Acne Rosacea

Faculty/Faculty Disclosure Statement

Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
Department of Dermatology
University of California, Davis
Medical Director
Center for Dermatology and Laser Surgery
Sacramento, Calif.
Consultant: Stiefel Laboratories, Inc.

Diane S. Berson, MD
Assistant Professor of Dermatology
Weill Medical College of Cornell University
New York, NY
Advisory Boards: Allergan, Inc., Connectics Corporation, Dermik Laboratories, Galderma International, and Medicis Pharmaceuticals Corporation.

Michael H. Gold, MD
Gold Skin Care Center
Nashville, Tenn.
No financial relationships to disclose.

Mary P. Lupo, MD
Clinical Professor of Dermatology
Tulane University Medical School
New Orleans, LA
Consultant: Stiefel Laboratories, Inc., Allergan and Dermik

Barry A. Solomon, MD, JD
Assistant Clinical Professor of Dermatology
Kings County Hospital Center
SUNY Health Science Center
Brooklyn, NY
Consultant: Stiefel Laboratories, Inc. He also discusses the investigational use of clindamycin 1% and benzoyl peroxide 5% for the treatment of acne rosacea.

Target Audience

This activity has been designed for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris and acne rosacea.

Copyright © 2005 by International Medical News Group

To view the supplement, click the image above.

A supplement to Pediatric News.
Supported by an educational grant from Stiefel.
The articles in this supplement are based on presentations made during the Skin Disease Education Foundation's 29th Annual Hawaii Dermatology Seminar, on March 18-24, 2005, in Maui, Hawaii.

• The Importance of Vehicle in Acne Therapy
• Acne Management: Treatment Strategies and Challenges
• Cosmetic Management of Patients with Acne Vulgaris and Acne Rosacea
• The Resurgence of Benzoyl Peroxide in Acne Therapy
• New Treatment Options for Acne Rosacea

Faculty/Faculty Disclosure Statement

Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
Department of Dermatology
University of California, Davis
Medical Director
Center for Dermatology and Laser Surgery
Sacramento, Calif.
Consultant: Stiefel Laboratories, Inc.

Diane S. Berson, MD
Assistant Professor of Dermatology
Weill Medical College of Cornell University
New York, NY
Advisory Boards: Allergan, Inc., Connectics Corporation, Dermik Laboratories, Galderma International, and Medicis Pharmaceuticals Corporation.

Michael H. Gold, MD
Gold Skin Care Center
Nashville, Tenn.
No financial relationships to disclose.

Mary P. Lupo, MD
Clinical Professor of Dermatology
Tulane University Medical School
New Orleans, LA
Consultant: Stiefel Laboratories, Inc., Allergan and Dermik

Barry A. Solomon, MD, JD
Assistant Clinical Professor of Dermatology
Kings County Hospital Center
SUNY Health Science Center
Brooklyn, NY
Consultant: Stiefel Laboratories, Inc. He also discusses the investigational use of clindamycin 1% and benzoyl peroxide 5% for the treatment of acne rosacea.

Target Audience

This activity has been designed for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris and acne rosacea.

Copyright © 2005 by International Medical News Group

To view the supplement, click the image above.

A supplement to Pediatric News.
Supported by an educational grant from Stiefel.
The articles in this supplement are based on presentations made during the Skin Disease Education Foundation's 29th Annual Hawaii Dermatology Seminar, on March 18-24, 2005, in Maui, Hawaii.

• The Importance of Vehicle in Acne Therapy
• Acne Management: Treatment Strategies and Challenges
• Cosmetic Management of Patients with Acne Vulgaris and Acne Rosacea
• The Resurgence of Benzoyl Peroxide in Acne Therapy
• New Treatment Options for Acne Rosacea

Faculty/Faculty Disclosure Statement

Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
Department of Dermatology
University of California, Davis
Medical Director
Center for Dermatology and Laser Surgery
Sacramento, Calif.
Consultant: Stiefel Laboratories, Inc.

Diane S. Berson, MD
Assistant Professor of Dermatology
Weill Medical College of Cornell University
New York, NY
Advisory Boards: Allergan, Inc., Connectics Corporation, Dermik Laboratories, Galderma International, and Medicis Pharmaceuticals Corporation.

Michael H. Gold, MD
Gold Skin Care Center
Nashville, Tenn.
No financial relationships to disclose.

Mary P. Lupo, MD
Clinical Professor of Dermatology
Tulane University Medical School
New Orleans, LA
Consultant: Stiefel Laboratories, Inc., Allergan and Dermik

Barry A. Solomon, MD, JD
Assistant Clinical Professor of Dermatology
Kings County Hospital Center
SUNY Health Science Center
Brooklyn, NY
Consultant: Stiefel Laboratories, Inc. He also discusses the investigational use of clindamycin 1% and benzoyl peroxide 5% for the treatment of acne rosacea.

Target Audience

This activity has been designed for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris and acne rosacea.

Copyright © 2005 by International Medical News Group

To view the supplement, click the image above.

A supplement to Pediatric News.
Supported by an educational grant from Stiefel.
The articles in this supplement are based on a faculty interview and reviews of selected posters that were presented at a medical conference held February 18-22, 2005, in New Orleans.

• Combination Tazarotene and Clindamycin/Benzoyl Peroxide
• Use of Clindamycin 1%/Benzoyl Peroxide 5% Gel Alone and in Combination for Acne Vulgaris
• Patient Preference for Clindamycin/Benzoyl Peroxide Gel Formulations
• Quantitative Assessment of the Application and Consumption of Topical Acne Medication by Patients
• Sulfacetamide/Sulfur Combination With Sunscreen for Rosacea

Faculty/Faculty Disclosure Statement

James Q. Del Rosso, DO, FAOCD
University of Nevada
School of Medicine
Las Vegas
Received funding for clinical grants: Galderma S.A., Intendis Inc., Medicis Pharmaceutical Corporations, Stiefel Laboratories, Inc.
Consultant: Galderma, Intendis, Stiefel.
He discusses the use of metronidazole and azelaic acid as a once-a-day treatment for rosacea as opposed to twice daily.

Copyright © 2005 by International Medical News Group

To view the supplement, click the image above.

A supplement to Pediatric News.
Supported by an educational grant from Stiefel.
The articles in this supplement are based on a faculty interview and reviews of selected posters that were presented at a medical conference held February 18-22, 2005, in New Orleans.

• Combination Tazarotene and Clindamycin/Benzoyl Peroxide
• Use of Clindamycin 1%/Benzoyl Peroxide 5% Gel Alone and in Combination for Acne Vulgaris
• Patient Preference for Clindamycin/Benzoyl Peroxide Gel Formulations
• Quantitative Assessment of the Application and Consumption of Topical Acne Medication by Patients
• Sulfacetamide/Sulfur Combination With Sunscreen for Rosacea

Faculty/Faculty Disclosure Statement

James Q. Del Rosso, DO, FAOCD
University of Nevada
School of Medicine
Las Vegas
Received funding for clinical grants: Galderma S.A., Intendis Inc., Medicis Pharmaceutical Corporations, Stiefel Laboratories, Inc.
Consultant: Galderma, Intendis, Stiefel.
He discusses the use of metronidazole and azelaic acid as a once-a-day treatment for rosacea as opposed to twice daily.

Copyright © 2005 by International Medical News Group

To view the supplement, click the image above.

A supplement to Pediatric News.
Supported by an educational grant from Stiefel.
The articles in this supplement are based on a faculty interview and reviews of selected posters that were presented at a medical conference held February 18-22, 2005, in New Orleans.

• Combination Tazarotene and Clindamycin/Benzoyl Peroxide
• Use of Clindamycin 1%/Benzoyl Peroxide 5% Gel Alone and in Combination for Acne Vulgaris
• Patient Preference for Clindamycin/Benzoyl Peroxide Gel Formulations
• Quantitative Assessment of the Application and Consumption of Topical Acne Medication by Patients
• Sulfacetamide/Sulfur Combination With Sunscreen for Rosacea

Faculty/Faculty Disclosure Statement

James Q. Del Rosso, DO, FAOCD
University of Nevada
School of Medicine
Las Vegas
Received funding for clinical grants: Galderma S.A., Intendis Inc., Medicis Pharmaceutical Corporations, Stiefel Laboratories, Inc.
Consultant: Galderma, Intendis, Stiefel.
He discusses the use of metronidazole and azelaic acid as a once-a-day treatment for rosacea as opposed to twice daily.

Copyright © 2005 by International Medical News Group

To view the supplement, click the image above.